COVID-19 vaccine – Long term immune decline and breakthrough infections

• Published in: Vaccine Vol. 39; no. 48; pp. 6984 - 6989
• Main Authors: Khoury, Johad, Najjar-Debbiny, Ronza, Hanna, Ayman, Jabbour, Adel, Abu Ahmad, Yara, Saffuri, Amer, Abu-Sinni, Majdole, Shkeiri, Rashed, Elemy, Ameer, Hakim, Fahed
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 26.11.2021; Elsevier Limited
• Subjects: Age groups; Antibodies; Antibody; Asymptomatic; BNT162 Vaccine; Booster; Coronaviruses; COVID; COVID-19; COVID-19 Vaccines; Decision making; Drug dosages; Humans; Immunogenicity; Immunogenicity, Vaccine; Infections; mRNA; Polymerase chain reaction; Prospective Studies; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Short Communication; Vaccine; Vaccines; COVID; Vaccine; Immunogenicity; Antibody; Booster

Since the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and decision making regarding a booster remains a top priority worldwide, a decision that should be made based on breakthrough infection rate and ant...